Apremilast Drug Asset Due Diligence Report 2026

This Apremilast Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

209

Registered trials

193

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Apremilast can convert its Small molecule drug profile and PDE4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Apremilast (query alias: apremilast)
Modality / target	Small molecule drug; PDE4; PDE4 inhibitors
Highest global status	Approved
Originator	Celgene Corp.
Active developers	Accord Healthcare SL, Amgen, Inc., Amgen KK

The MCP disease footprint includes Pustulosis of Palms and Soles, Behcet Syndrome, Oral Ulcer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07432386	Phase 4	Not yet recruiting	80	Change in Dermatology Life Quality Index (DLQI) Score
NCT07352566	Phase 4	Not yet recruiting	10	Number of participants with adverse events
NCT07398651	Not Applicable	Not yet recruiting	60	Disease Activity Index for Psoriatic Arthritis

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EFFECT OF APREMILAST ON FINGERNAIL BED INFLAMMATION IN PATIENTS WITH PSORIATIC ARTHRITIS AND DACTYLITIS: DYNAMIC CONTRAST-ENHANCED MRI RESULTS FROM THE PHASE 4 MOSAIC STUDY

Phase 4; n=29; evaluation: Positive. Reported fields: LDI(Week 24) = −37.4 Point

EFFICACY OF APREMILAST IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS BY BASELINE ACTIVE JOINT COUNT: A POST HOC ANALYSIS OF THE FOREMOST STUDY

Phase 3; n=308; evaluation: Positive. Reported fields: PASDAS(good response) = 20.0 % ; -

Apremilast for the Treatment of Refractory Erythema Multiforme

Phase 2; n=6; evaluation: not stated. Reported fields: Erythema Multiforme Flares on Medication(Mean) = 1.7 Number of flares (Full Range, 0 - 4); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Apremilast addresses Pustulosis of Palms and Soles, Behcet Syndrome, Oral Ulcer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-27	Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China	Approved	Financial terms not disclosed
2020-08-03	AbbVie, Amgen, and Takeda collaborate on the I-SPY clinical trial to investigate the efficacy of cenicriviroc, Otezla, and Firazyr in treating Covid-19.	Approved	Financial terms not disclosed
	Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion	Approved	US$13,400.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Transdermal administration of PDE4 inhibitors for reduction in adverse events”. The milestone feed surfaced a patent-application signal described as “Apremilast inhalation dry powder as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of apremilast drug intermediate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO